[HTML][HTML] Molecular magnetic resonance imaging in cancer

M Haris, SK Yadav, A Rizwan, A Singh, E Wang… - Journal of translational …, 2015 - Springer
The ability to identify key biomolecules and molecular changes associated with cancer
malignancy and the capacity to monitor the therapeutic outcome against these targets is …

Magnetic resonance imaging of cancer metabolism with hyperpolarized 13C-labeled cell metabolites

RL Hesketh, KM Brindle - Current opinion in chemical biology, 2018 - Elsevier
Highlights•Hyperpolarization of 13 C substrates by dissolution dynamic nuclear polarization
can increase NMR signal by> 10 4.•Many hyperpolarized substrates have been developed …

Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer

AJ Walsh, RS Cook, HC Manning, DJ Hicks… - Cancer research, 2013 - AACR
Abnormal cellular metabolism is a hallmark of cancer, yet there is an absence of quantitative
methods to dynamically image this powerful cellular function. Optical metabolic imaging …

Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment

D Roblyer, S Ueda, A Cerussi… - Proceedings of the …, 2011 - National Acad Sciences
Approximately 8–20% of breast cancer patients receiving neoadjuvant chemotherapy fail to
achieve a measurable response and endure toxic side effects without benefit. Most clinical …

Breast cancer recurrence diagnosis suspected on tumor marker rising: Value of whole‐body 18FDG‐PET/CT imaging and impact on patient management

L Champion, E Brain, AL Giraudet, E Le Stanc… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Breast cancer recurrence is often suspected on tumor marker rising in
asymptomatic patients. The value of fluorine‐18 fluorodeoxyglucose (18FDG)–positron …

18F-Fluoroestradiol

L Sundararajan, HM Linden, JM Link, KA Krohn… - Seminars in nuclear …, 2007 - Elsevier
Estrogen receptor (ER) expression is an important determinant of breast cancer behavior
and is critical for response to endocrine therapies such as tamoxifen and aromatase …

Current trends in preclinical PET system design

CS Levin, H Zaidi - PET clinics, 2007 - Elsevier
PET is used in laboratory small-animal research to visualize and track certain molecular
processes associated with diseases such as cancer, heart disease, and neurologic …

Monitoring predominantly cytostatic treatment response with 18F-FDG PET

KB Contractor, EO Aboagye - Journal of Nuclear Medicine, 2009 - Soc Nuclear Med
18 F-FDG PET and, more recently, PET/CT have been established as response biomarkers
for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer …

[HTML][HTML] A method for model-free partial volume correction in oncological PET

F Hofheinz, J Langner, J Petr, B Beuthien-Baumann… - EJNMMI research, 2012 - Springer
Background As is well known, limited spatial resolution leads to partial volume effects (PVE)
and consequently to limited signal recovery. Determination of the mean activity …

GlucoCEST MRI for the Evaluation Response to Chemotherapeutic and Metabolic Treatments in a Murine Triple-Negative Breast Cancer: A Comparison with[18F]F …

M Capozza, A Anemone, C Dhakan… - Molecular Imaging and …, 2022 - Springer
Purpose Triple-negative breast cancer (TNBC) patients have usually poor outcome after
chemotherapy and early prediction of therapeutic response would be helpful.[18F] F-FDG …